Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future

Hui Kong Gan, Bryan W. W. Day, Rosemary Harrup, Terrance G. G. Johns, Zarnie Lwin, Andrew Mark Scott, Hao-Wen Sim, Eng-Siew Koh

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Purpose of ReviewThis review identifies challenges and barriers to successful development of drugs in neuro-oncology trials at the preclinical, clinical and translational stages that we believe has contributed to poor outcomes for patients over the last 30 years.Recent FindingsSeveral key strategies have been proposed by leading groups to address these and improve patient outcomes. Better preclinical testing using more sophisticated and clinically relevant models is needed. A greater focus on assessing blood-brain barrier penetrance and targeting key biological processes such as tumour heterogeneity and immune response is vital. Adopting innovative trial designs permitting faster results and addressing key issues (including molecular heterogeneity and combinatorial approaches) is highly desirable. A stronger translational focus is also clearly needed.Implementation of these strategies is already starting to occur. Maintaining and increasing these novel approaches will require coordinated efforts between clinicians, scientists, industry and funding/regulator bodies.
Original languageEnglish
Pages (from-to)589-598
Number of pages10
JournalCurrent Oncology Reports
Volume25
Issue number6
Early online date28 Mar 2023
DOIs
Publication statusPublished - Jun 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future'. Together they form a unique fingerprint.

Cite this